Treatment of Aggressive Localized Lymphoma
Launched by FRENCH INNOVATIVE LEUKEMIA ORGANISATION · Feb 11, 2009
Trial Information
Current as of May 23, 2025
Terminated
Keywords
ClinConnect Summary
CHOP 14 R regimen of chemotherapy is a good standard in the treatment of agressive and localized B lymphoma.
Interest of the radiotheraphy
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 and \< 75 years
- • Diffuse B large cell lymphoma , CD 20+
- • Ann Arbor stage I or II withe a bulk \<7 cm
- • stage i ou II confirmed by the PET-scan
- • No previously treated
- • HIV negative
- • Signed Informed consent
- Exclusion Criteria:
- • Age\< 18 and \> 75 years
- • other type of lymphoma
- • CD20 negative
- • Ann Arbor stage \>II or bulk \> 7 cm
- • HIV positive
- • Contraindication to Rituximab use according to Sm PC
- • Containdication to antracyclin
- • cancer or history of cancer , excepted in situ cancer of the cervix or skin epithelioma
- • Refusal of sign the informed consent
About French Innovative Leukemia Organisation
The French Innovative Leukemia Organisation (FILO) is a leading clinical trial sponsor dedicated to advancing research and treatment options for leukemia. Committed to enhancing patient outcomes, FILO collaborates with top-tier medical institutions and researchers to facilitate innovative clinical trials that explore new therapies and improve existing treatment protocols. By fostering a multidisciplinary approach, FILO aims to accelerate the development of groundbreaking therapies while prioritizing patient safety and ethical standards in clinical research. Through its initiatives, FILO seeks to transform the landscape of leukemia treatment and contribute to the global fight against this challenging disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rennes, , France
Patients applied
Trial Officials
Thierry LAMY, MD PhD
Principal Investigator
French Innovative Leukemia Organisation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials